These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3535345)

  • 1. [Use of small, moderate and large doses of cytarabine (ARA-C) in the treatment of leukemia and other diseases of the hematopoietic system].
    Robak T
    Acta Haematol Pol; 1986; 17(1-2):63-70. PubMed ID: 3535345
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of small doses cytosine arabinoside (Ara-C) on leukemic cells in vitro and in vivo. Results in patients with leukemia and myelodysplastic syndrome.
    Kuliczkowski K; Kotlerek-Haus S; Frydecka I; Sedek K; Nowicka J
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):738-48. PubMed ID: 2436986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experiences with low-dos Ara-C in the therapy of hematological neoplasms].
    Jacky E; Frick P
    Ther Umsch; 1988 Feb; 45(2):119-23. PubMed ID: 3358244
    [No Abstract]   [Full Text] [Related]  

  • 4. [Myelodysplastic syndrome and myelogenous leukemia. Treatment with low-dose cytarabine].
    Waage A; Hammerstrøm J; Lødemel B; Hoff JE; Langtind J
    Tidsskr Nor Laegeforen; 1986 Feb; 106(6):496-7. PubMed ID: 3457484
    [No Abstract]   [Full Text] [Related]  

  • 5. [A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
    Maruta A; Miyashita H; Kodama F; Harano H; Kanamori H; Takahashi K; Noguchi T; Matsuzaki M; Ogawa K; Motomura S
    Rinsho Ketsueki; 1988 Jan; 29(1):8-13. PubMed ID: 3385938
    [No Abstract]   [Full Text] [Related]  

  • 6. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
    Yee KW; Cortes J; Ferrajoli A; Garcia-Manero G; Verstovsek S; Wierda W; Thomas D; Faderl S; King I; O'brien SM; Jeha S; Andreeff M; Cahill A; Sznol M; Giles FJ
    Leuk Res; 2006 Jul; 30(7):813-22. PubMed ID: 16478631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytarabine-induced pericarditis].
    Yamada T; Tsurumi H; Hara T; Sawada M; Oyama M; Moriwaki H
    Rinsho Ketsueki; 1998 Nov; 39(11):1115-20. PubMed ID: 9866424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More on low-dose Ara-C.
    Bernardeschi P; Bonechi I
    Haematologica; 1986; 71(1):86. PubMed ID: 3084362
    [No Abstract]   [Full Text] [Related]  

  • 9. [Ventricular fibrillation in a patient with myelodysplastic syndrome treated with small doses of cytarabine].
    Drzewoski J; Krykowski E; Robak T; Jerzmanowski P; Kusowska J; Koźbiał H
    Kardiol Pol; 1989; 32(4):225-8. PubMed ID: 2622113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with cytosine arabinoside and granulocyte colony-stimulating factor in patients with myelodysplastic syndrome and its leukemic phase.
    Im T; Yamane T; Mugitani A; Hiyoshi M; Park K; Tatsumi N
    Int J Hematol; 1994 Oct; 60(3):215-23. PubMed ID: 7532031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment with low dose Ara-C in de novo acute myeloid leukemia with trilineage myelodysplasia.
    Kawano F; Nishimura Y; Tsukamoto A; Satoh M; Sanada I; Shido T
    Int J Hematol; 1992 Feb; 55(1):101-2. PubMed ID: 1581580
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose Ara-C in the treatment of myelodysplastic syndromes.
    Bogdanić V; Labar B; Mrsić M; Nemet D; Serventi-Seiwerth R
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():26-7. PubMed ID: 2697395
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience.
    Cheson BD; Simon R
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):126-33. PubMed ID: 3589688
    [No Abstract]   [Full Text] [Related]  

  • 15. Low-dose cytarabine in myelodysplastic syndromes and acute leukemia. A comment.
    Cacciola E; Di Raimondo F; Guglielmo P; Milone G; Giustolisi R
    Acta Haematol; 1986; 75(2):125-6. PubMed ID: 3090823
    [No Abstract]   [Full Text] [Related]  

  • 16. High-dose methylprednisolone, low-dose cytosine arabinoside, and mitoxantrone in children with myelodysplastic syndromes.
    Hiçsönmez G; Tuncer AM; Sayli T; Güler E; Cetin M; Ozbek N; Mufti GJ
    Hematol Pathol; 1995; 9(3-4):185-93. PubMed ID: 8655463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
    Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
    Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
    Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
    Heidel F; Cortes J; Rücker FG; Aulitzky W; Letvak L; Kindler T; Huber C; Döhner H; Kantarjian H; Fischer T
    Cancer; 2007 Mar; 109(5):907-14. PubMed ID: 17285599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.